Year 2022 / Volume 114 / Number 2
Letter
Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results

118-119

DOI: 10.17235/reed.2021.8320/2021

Federico Argüelles-Arias, Paula Fernández Álvarez, Luisa Castro Laria, Belén Maldonado Pérez, María Belvis Jiménez, Vicente Merino-Bohórquez, Ángel Caunedo Álvarez, Miguel Ángel Calleja Hernández,

Abstract
A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. The use of this new formulation was requested, in an effort to limit patient attendance at intravenous infusion centers and to maintain biological treatment during the COVID-19 pandemic. The objective of this observational, retrospective and descriptive study was to assess CT-P13 efficacy and safety after switching from intravenous to a subcutaneous formulation in patients with IBD receiving maintenance therapy. This article shows preliminary results after six months of follow-up.
Share Button
New comment
Comments
No comments for this article
Related articles

Digestive Diseases Image

Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy

DOI: 10.17235/reed.2022.9218/2022

Digestive Diseases Image

Acute respiratory failure secondary to megaesophagus: think beyond COVID-19

DOI: 10.17235/reed.2022.8847/2022

Letter

Surgical acute abdomen and COVID-19 vaccination

DOI: 10.17235/reed.2022.8721/2022

Letter

AMA-positive hepatitis induced by the SARS-CoV-2 vaccine.

DOI: 10.17235/reed.2022.8533/2021

Letter

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Letter

COVID-19 and aorto-enteric fistula

DOI: 10.17235/reed.2021.8272/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Letter

Pneumoperitoneum and COVID-19. A causal association?

DOI: 10.17235/reed.2021.7877/2021

Letter

COVID-19 and the liver: the chicken or the egg dilemma

DOI: 10.17235/reed.2021.7861/2021

Letter

Pancreatic injury and acute pancreatitis in COVID-19 patients

DOI: 10.17235/reed.2021.7807/2021

Editorial

Leading in turbulent times with the aim to serve

DOI: 10.17235/reed.2020.7684/2020

Letter

Pancreatic injury in COVID-19: pathogenesis and challenges

DOI: 10.17235/reed.2020.7541/2020

Letter

SARS-CoV-2 and acute pancreatitis: a new etiological agent?

DOI: 10.17235/reed.2020.7481/2020

Letter

Latin American authorship in scientific production on COVID-19

DOI: 10.17235/reed.2020.7432/2020

Letter

COVID-19. Immunothrombosis and the gastrointestinal tract

DOI: 10.17235/reed.2020.7292/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Citation tools
Argüelles-Arias F, Fernández Álvarez P, Castro Laria L, Maldonado Pérez B, Belvis Jiménez M, Merino-Bohórquez V, et all. Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results. 8320/2021


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1580 visits.
This article has been downloaded 426 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 01/09/2021

Accepted: 03/09/2021

Online First: 14/09/2021

Published: 07/02/2022

Article Online First time: 13 days

Article editing time: 159 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology